Clinical trials: Active Population
Mid Face Volume Deficit
A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants
The cumulative effect of aging and environmental exposures (ie, ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles, discoloration, laxity, and roughness of sun exposed skin.
- Trial name
- NCT05452070
- Testing
- HArmonyCa Lidocaine Injectable Gel
- Where
- 12 sites in Canada, Spain and 1 more
- Volunteers
- 171 people
- Sponsor
- Allergan
Rheumatoid Arthritis
GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
The study objective is to identify potential safety risks of the transition from US-licensed Rituxan® or EU-approved MabThera® to GP2013 (proposed biosimilar product) as compared to continuous treatment with the originator…
- Trial name
- ASSIST-RT (NCT02514772)
- Testing
- GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
- Where
- 65 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Sandoz
Pulmonary Disease, Chronic Obstructive
Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease
This study was designed to look at effects of salmeterol/fluticasone propionate compared to placebo on airway inflammation in patients with chronic obstructive airways disease
- Trial name
- NCT00268177
- Testing
- Salmeterol/fluticasone propionate 50/500mcg Diskus
- Where
- 20 sites in Denmark, Estonia and 6 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Bunionectomy, Pain
A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy
The main objective of this trial is to demonstrate the efficacy and safety of multiple-dose application of oral application of CG5503 IR 75mg compared to placebo and to assess safety and tolerability of CG5503 IR 75mg in subjects…
- Conditions
- Bunionectomy, Pain, Postoperative Pain, Acute Pain
- Trial name
- NCT00609466
- Testing
- CG5503 IR, Morphine
- Where
- 6 sites in United States
- Volunteers
- 291 people
- Sponsor
- Grünenthal GmbH
Crohn's Disease, IBD
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical…
- Trial name
- INTREPID (NCT03759288)
- Testing
- Brazikumab low dose, Brazikumab high dose, Humira®
- Where
- 102 sites in United States, Canada and 15 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years.
- Trial name
- NCT07505888
- Testing
- experimental vaccine, active comparator vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Sleep Deprivation
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.
- Trial name
- NCT01096680
- Testing
- SPD489 20 mg, SPD489 50 mg, SPD489 70 mg
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Shire
Thromboembolism, Arthroplasty, Replacement, Hip
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in…
- Trial name
- NCT00168818
- Testing
- dabigatran etexilate, enoxaparin
- Where
- 116 sites in Australia, Austria and 14 more
- Volunteers
- 3,494 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- DIAMOND (NCT00321490)
- Testing
- Quetiapine fumarate, Duloxetine
- Where
- 34 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Rosacea
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
- Trial name
- NCT03689010
- Testing
- Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
- Where
- United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Oral Contraceptive, Headache
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or…
- Conditions
- Oral Contraceptive, Headache, Pelvic Pain
- Trial name
- NCT00778609
- Testing
- EV/DNG (Qlaira, BAY86-5027)
- Where
- 63 sites in Australia, Finland and 7 more
- Volunteers
- 449 people
- Sponsor
- Bayer
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
- Trial name
- NCT00364091
- Testing
- R89674 0.025% ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 365 people
- Sponsor
- Vistakon Pharmaceuticals
Rheumatoid Arthritis
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding.
- Trial name
- OSKIRA-Asia-1 (NCT01569074)
- Testing
- Fostamatinib
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.
- Trial name
- NCT05405725
- Testing
- ENZ215, Prolia
- Where
- 48 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 504 people
- Sponsor
- Enzene Biosciences Ltd.
Hypertension
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
- Trial name
- NCT01876368
- Testing
- LCZ696, Olmesartan
- Where
- 51 sites in United States, Argentina and 5 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Insomnia Disorder
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
- Trial name
- NCT06975514
- Testing
- YZJ-1139, Zolpidem
- Where
- 16 sites in China
- Volunteers
- 61 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Hypertension
Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
A study to compare the effects of Diovan or Atenolol taken for 12 weeks on platelet function of patients who have mild to moderately severe hypertension
- Trial name
- NCT00171756
- Testing
- valsartan/atenolol
- Where
- Switzerland
- Volunteers
- 92 people
- Sponsor
- Novartis
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.